{"schema_version":"1.0","type":"article","title":"一季狂賣 230 億美元，禮來卻急著買下一個藥王","url":"https://drugnews.com.tw/articles/2026-08-18-eli-lilly-tirzepatide-next-drug-king.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-18-eli-lilly-tirzepatide-next-drug-king.md","lang":"zh-Hant","date":"2026-08-18","publish_at":"2026-08-18T08:00:00+08:00","updated_at":"2026-08-18","category":"商業分析系列","topic":"商業分析系列","tags":["Eli Lilly","禮來","Tirzepatide","Mounjaro","Zepbound","GLP-1","Retatrutide","Orforglipron","康霈"],"summary":"Tirzepatide 讓禮來同時吃下糖尿病與減重兩個大市場，但收入集中、價格壓力與下一代產品接班，才是市場真正該看的投資問題。","key_points":[],"facts":[],"sections":["參考資料","免責聲明"],"references":[{"title":"[Eli Lilly 2026 Q2 Form 10-Q]","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/lly-20260630.htm"},{"title":"[Eli Lilly 2026 Q2 sales and earnings press release]","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/59478/000005947826000077/q226lillysalesandearningsp.htm"},{"title":"[FDA approval announcement for Foundayo]","source":"","date":"","url":"https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program"},{"title":"[Foundayo prescribing information]","source":"","date":"","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf"},{"title":"[NEJM SURMOUNT-5 tirzepatide versus semaglutide]","source":"","date":"","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2416394"},{"title":"[Lilly Zepbound versus Wegovy SURMOUNT-5 release]","source":"","date":"","url":"https://investor.lilly.com/news-releases/news-release-details/zepbound-tirzepatide-showed-superior-weight-loss-over-wegovy"},{"title":"[Lilly retatrutide TRIUMPH-1 Phase 3 topline release]","source":"","date":"","url":"https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html"},{"title":"[Novo Nordisk 2026 Q2 results]","source":"","date":"","url":"https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916590"},{"title":"[Lilly acquisition and infectious-disease portfolio releases]","source":"","date":"","url":"https://investor.lilly.com/news-releases/news-release-details/lilly-announces-three-acquisitions-build-infectious-disease"},{"title":"[Lilly Indiana manufacturing investment]","source":"","date":"","url":"https://investor.lilly.com/news-releases/news-release-details/lilly-commits-additional-45-billion-across-indiana-manufacturing"},{"title":"[Caliway CBL-514 and tirzepatide combination trial announcement]","source":"","date":"","url":"https://www.caliwaybiopharma.com/news-detail/Caliway-Submits-IND-for-Cbl-514-Combination-Therapy-Phase-2/"},{"title":"查證截止日：2026 年 8 月 18 日。","source":"","date":"","url":""}],"images":[{"alt":"圖1｜禮來第二季營收與 tirzepatide 收入集中度圖解","url":"https://drugnews.com.tw/assets/articles/eli-lilly-tirzepatide-next-drug-king/figure-01.png"},{"alt":"圖2｜Foundayo 與 retatrutide 接棒 tirzepatide 的產品路徑圖","url":"https://drugnews.com.tw/assets/articles/eli-lilly-tirzepatide-next-drug-king/figure-02.png"},{"alt":"圖3｜禮來以併購尋找第二座成長山脈的資本配置圖","url":"https://drugnews.com.tw/assets/articles/eli-lilly-tirzepatide-next-drug-king/figure-03.png"},{"alt":"圖4｜康霈 CBL-514 與 tirzepatide 研究邊界示意圖","url":"https://drugnews.com.tw/assets/articles/eli-lilly-tirzepatide-next-drug-king/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/eli-lilly-tirzepatide-next-drug-king/cover-editorial.jpg","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-18）。一季狂賣 230 億美元，禮來卻急著買下一個藥王。https://drugnews.com.tw/articles/2026-08-18-eli-lilly-tirzepatide-next-drug-king.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-08-18-eli-lilly-tirzepatide-next-drug-king-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}